His primary scientific interests are in Internal medicine, Gastroenterology, Immunology, Hepatitis C and Hepatitis B virus. The Internal medicine study combines topics in areas such as Pegylated interferon, Ribavirin, Hepatitis C virus and Surgery. His Hepatitis C virus study combines topics from a wide range of disciplines, such as Steatosis and Genotype.
His research in Gastroenterology intersects with topics in Fibrosis, Liver biopsy and Peginterferon alfa-2a. His work investigates the relationship between Hepatitis C and topics such as Simeprevir that intersect with problems in Daclatasvir. In his study, Lamivudine, Viral load and Viral hepatitis is inextricably linked to Hepatitis B, which falls within the broad field of Hepatitis B virus.
His primary areas of investigation include Internal medicine, Gastroenterology, Immunology, Virology and Hepatitis C virus. His studies in Internal medicine integrate themes in fields like Ribavirin and Hepatitis B virus. Patrick Marcellin has included themes like Fibrosis, Chronic hepatitis, Surgery and Peginterferon alfa-2a in his Gastroenterology study.
His Virology research incorporates elements of Polymerase chain reaction and Genotype. Patrick Marcellin combines subjects such as Antibody and Liver biopsy with his study of Hepatitis C virus. His Hepatitis C study combines topics in areas such as Prospective cohort study and Steatosis.
Internal medicine, Gastroenterology, Hepatitis B virus, Hepatitis B and HBsAg are his primary areas of study. His studies deal with areas such as HBeAg and Ribavirin as well as Internal medicine. His Gastroenterology study incorporates themes from Surgery and Hepatitis C virus.
His work deals with themes such as Discontinuation and Combination therapy, which intersect with Hepatitis B virus. His Hepatitis B research also works with subjects such as
His scientific interests lie mostly in Internal medicine, Gastroenterology, Cirrhosis, Hepatocellular carcinoma and Hepatitis B virus. His work on Ribavirin expands to the thematically related Internal medicine. His Gastroenterology research integrates issues from Surgery, Hepatitis C virus, HBsAg, HBeAg and Hepatitis C.
The study incorporates disciplines such as Stage, Liver biopsy and Fibrosis in addition to HBeAg. While the research belongs to areas of Cirrhosis, Patrick Marcellin spends his time largely on the problem of Liver disease, intersecting his research to questions surrounding Decompensation. Patrick Marcellin interconnects Prothrombin time and Cohort in the investigation of issues within Hepatocellular carcinoma.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Stephanos J. Hadziyannis;Hoel Sette;Timothy R. Morgan;Vijayan Balan.
Annals of Internal Medicine (2004)
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
Thierry Poynard;Patrick Marcellin;Samuel S Lee;Christian Niederau.
The Lancet (1998)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson;John G. McHutchison;Geoffrey Dusheiko;Adrian M. Di Bisceglie.
The New England Journal of Medicine (2011)
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.
Marianne Ziol;Adriana Handra-Luca;Adrien Kettaneh;Christos Christidis.
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Patrick Marcellin;Ting Tsung Chang;Seng Gee Lim;Myron J. Tong.
The New England Journal of Medicine (2003)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal;Stefan Zeuzem;Paul Kwo;Mario Chojkier.
The New England Journal of Medicine (2014)
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
George K.K. Lau;Teerha Piratvisuth;Kang Xian Luo;Patrick Marcellin.
The New England Journal of Medicine (2005)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin;Edward J Gane;Maria Buti;Nezam H Afdhal.
The Lancet (2013)
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
Patrick Marcellin;George K.K. Lau;Ferruccio Bonino;Patrizia Farci.
The New England Journal of Medicine (2004)
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Stephanos J. Hadziyannis;Nicolaos C. Tassopoulos;E. Jenny Heathcote;Ting-Tsung Chang.
The New England Journal of Medicine (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: